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Hormonal resuscitation therapy in the management
of the brain-dead potential organ donorIn the early 1980s, experiments at the University of Cape
Town Medical School by Novitzky and his colleagues
demonstrated that brain death, as suffered by all deceased
organ donors, had several detrimental effects on organ
function. These experimental observations, and their more
recent impact on the clinical management of human brain-
dead potential organ donors, have recently been
reviewed.1
Initially, the extreme vasoconstriction that takes place
when the brain is compressed within the skull leads to
a short-lived, but devastating, catecholamine ‘storm’, that
is a result of endogenous catecholamine release from post-
ganglionic sympathetic nerve endings.2e4 This results in
a significant elevation in systemic vascular resistance, lead-
ing to systemic hypertension. In extreme cases, the great
increase in systemic vascular resistance can cause acute
left ventricular failure, with a fall in cardiac output, and
even acute transient mitral valve regurgitation, associated
with an increase in left atrial pressure. In view of the blood
volume displacement into the venous compartment, with
pulmonary volume overloading, pulmonary edema and
hemorrhage may also develop.4,5 This period of hemody-
namic stress is associated with cardiac arrhythmias, and is-
chemic changes may be seen on the electrocardiogram.3
The transient hemodynamic sequelae of brain death can
lead to significant histopathological injury to the myocar-
dium, that can include cell necrosis, and to the lungs.3e5
These changes alone may jeopardize the immediate func-
tion of the heart and lungs after transplantation.
However, of even more interest and significance are the
endocrine changes that were observed after the induction
of brain death.2,4 Plasma levels of free triiodothyronine
(T3) and free thyroxine (T4) fell to less than half of control
levels within 1 h, and became undetectable a few hours
later, even though thyroid-stimulating hormone showed
no significant change. Insulin and cortisol levels showed sig-
nificant declines, and antidiuretic hormone was undetect-
able within 6 h.6
These endocrine changes were demonstrated to be
associated with a marked reduction in utilization of1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. Publish
doi:10.1016/j.ijsu.2006.11.007glucose, pyruvate, and palmitate, with an accumulation
of tissue and plasma lactate and plasma-free fatty acids,
indicating a decrease in aerobic metabolism in the donor.7
Myocardial energy stores are rapidly depleted,8 and it is
these changes that almost certainly account for the fact
that most brain-dead subjects undergo hemodynamic col-
lapse within 24e48 h, if untreated. These observations indi-
cate that, following brain death, there is a progressive
mitochondrial inhibition, and eventually all cells lose the
ability to generate ATP via the Kreb’s cycle.
Further experimental studies assessed the effect of
hormonal replacement therapy after brain death.6,8 Intra-
venous therapy in experimental animals, consisting of T3,
cortisol, and insulin, demonstrated a substantial increase
in glucose, pyruvate, and palmitate utilization, accompa-
nied by a reduction of plasma lactate and free fatty acids,
indicating a reversal from anaerobic to aerobic metabo-
lism.7 Myocardial energy stores returned to normal or
near-normal values, as did cardiac output and stroke
volume.6,8
In an initial clinical trial of hormone replacement
therapy at Groote Schuur Hospital in Cape Town, 21
consecutive brain-dead donors were treated with tradi-
tional therapy (IV fluids, inotropes, and bicarbonate) but,
in addition, received T3, cortisol, and insulin at hourly
intervals.9 When compared with 26 historical control donors
treated only with standard therapy, the hormone-treated
donors showed restoration of their low T3 levels to normal,
accompanied by significant hemodynamic improvement,
with significantly less demand for inotropic support and
bicarbonate. In addition, all electrocardiographic abnor-
malities disappeared and all 21 hormone-treated donor
hearts were transplanted with satisfactory immediate car-
diac function.
Several other groups investigated the role of hormonal
replacement therapy in brain-dead potential organ donors,
some of whom confirmed the data from the Cape Town
group, and others who did not (reviewed in Ref.1). These
discrepancies may have been for a number of reasons. For
example, not all brain-dead donors have total absence ofed by Elsevier Ltd. All rights reserved.
4 Editorialanterior pituitary function, some groups failed to measure
free-T3, not all donors are hemodynamically unstable and
therefore may not benefit from T3/T4 therapy, and an inad-
equate dosage of T3/T4 may have been administered.
However, in March 2001, a conference took place in the
US, attended by nearly 100 transplant professionals, with
the aim of maximizing the number of organs recovered and
transplanted from deceased donors.10 The conference rec-
ommended that 4-drug hormonal resuscitation (T3/T4,
methylprednisolone, insulin, and arginine vasopressin) of
donors with a left ventricular ejection fraction of <45%,
and/or unstable hemodynamics, should be initiated. The
conference further recommended that the United Network
for Organ Sharing (UNOS) should follow the conference
guidelines, a recommendation that was implemented by
UNOS.11
Recent data from UNOS have indicated that, when 3-
drug hormonal replacement (T3/T4, methylprednisolone,
vasopressin) is administered, there has been a 22.5%
greater number of organs transplanted from such donors
than from donors not so treated.12 The increased probabil-
ity of an organ being transplanted has been estimated to be
between 2.8 and 7.3% for the major organs. A second UNOS
study indicated that survival of patients whose donors have
received hormonal therapy was significantly greater than
those whose donors had not (89.9 vs 83.9%). In particular,
early heart graft dysfunction occurred in only 5.6% of pa-
tients when the organ came from a hormone-resuscitated
donor, but in 11.6% of patients when the donor had re-
ceived no hormonal therapy. Furthermore, if the donor
had received hormonal replacement therapy, significantly
improved one-year kidney and heart graft survivals were
demonstrated, although not for recipients of liver grafts.13
Almost 25 years after the initial experimental observa-
tions and the first clinical experience, therefore, hormonal
resuscitation is becoming more widely accepted. Whereas
only 8.8% of brain-dead organ donors in the US received
hormonal therapy in the year 2000, 19.9% received such
therapy in 2004.1
It has long been known that there is a significant
depletion of free-T3 in patients being supported by cardio-
pulmonary bypass, and the Cape Town group demonstrated
that the IV administration of T3 improves post-cardiopul-
monary bypass cardiac function and reverses adverse
metabolic changes.14,15 With regard to heart transplanta-
tion, they demonstrated the beneficial effect of treatment
if both donor and recipient had received hormonal resusci-
tation therapy.16,17
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